# Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer

> **NCT05747326** · PHASE2 · UNKNOWN · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 30 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** oral vinorelbine and capecitabine

## Key facts

- **NCT ID:** NCT05747326
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-01
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05747326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05747326, "Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05747326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*